Fox Chase Cancer Center News

PHILADELPHIA (June 16, 2020)—Researchers at Fox Chase Cancer Center uncovered a mechanism by which the protein PRR14 acts as a tether within the cell’s nucleus to link heterochromatin and the nuclear lamina, an important feature in understanding the changes in nuclear organization in cancer.

PHILADELPHIA (June 15, 2020) – Fox Chase Cancer Center announces the hiring of Andrea S. Porpiglia, MD, MSc, who will join the Department of Surgical Oncology in the Division of General Surgery on July 1, 2020. She will see patients at Fox Chase main campus and Fox Chase East Norriton.

PHILADELPHIA (June 11, 2020)— The Department of Bone Marrow Transplant and Cellular Therapies will be chaired by Henry Chi Hang Fung, MD, FACP, FRCPE, current director of the Bone Marrow Transplant Program and vice chair of the Department of Hematology/Oncology. The change is effective July 1, 2020.

PHILADELPHIA (June 11, 2020)— Health Psychology is the official journal for the Society for Health Psychology, which works to promote education and services in the psychology of health and illness. It publishes a wide range of research reports as well as systematic reviews and meta-analyses, critical reviews of issues in health psychology and behavioral medicine, methodological guidance and tutorials, and advances in research methods.

PHILADELPHIA (June 10, 2020)— The work could aid in the design of clinical studies that could ultimately lead to improved and personalized cancer treatments.

PHILADELPHIA (June 5, 2020)—Fox Chase faculty members will be hosting a virtual education presentation next Tuesday, June 9, from 5:30 to 6 pm, titled “From Bench to Bedside – Lung Cancer Treatments.”

PHILADELPHIA (Jun 1, 2020) – Fox Chase Cancer Center will host an online patient education event, “Together Facing Cancer and COVID-19,” at 5:30 p.m. on Thursday, June 4. Fox Chase understands that patients and caregivers have concerns and questions as they navigate their cancer journey in these challenging times, and the event will address many of those issues. Our panel of experts is here to help.

PHILADELPHIA (May 29, 2020)— The study ultimately concluded that treatment with dinutuximab plus irinotecan was not superior to the established second-line treatment for relapsed/refractory small cell lung cancer.